Welcome to our dedicated page for Astera Labs SEC filings (Ticker: ALAB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Astera Labs's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Astera Labs's regulatory disclosures and financial reporting.
Astera Labs, Inc. President and COO Gajendra Sanjay reported open-market sales of 94,971 shares of common stock on February 17, 2026. The shares were sold at weighted-average prices between $122.1576 and $126.3400 per share.
According to the disclosure, these shares were required to be sold to satisfy tax withholding obligations tied to vesting and settlement of previously granted restricted stock units, under a pre-arranged “sell to cover” election, and do not represent discretionary trades by Sanjay.
After these sales, he holds 1,531,301 shares directly. Estate-planning trusts associated with him hold an additional 5,864,213 shares in Trust 1, 695,000 shares in Trust 2, and 695,000 shares in Trust 3, for which he disclaims beneficial ownership except for any pecuniary interest.
Astera Labs, Inc. Chief Financial Officer Michael Truett reported automatic sales of 12,001 shares of common stock on February 17, 2026 to satisfy tax withholding from vested restricted stock units under a pre-arranged sell-to-cover election. Sale prices ranged around $122–$126 per share. Truett continues to hold 192,083 shares directly, while 450,281 additional shares are held by the Tate 1997 Living Trust, for which he disclaims beneficial ownership except for any pecuniary interest.
Astera Labs, Inc. General Counsel and Secretary Philip Mazzara reported automatic sales of 4,849 shares of common stock on February 17, 2026. The Form 4 notes these open-market sales were made solely to cover tax withholding obligations from vesting restricted stock units. After these transactions, he directly held 138,084 shares of common stock.
Astera Labs, Inc. submitted a Form 144 notice reporting proposed sales of Common Stock tied to the vesting of restricted stock units on 02/15/2026.
The filing lists prior sales by Philip Mazzara: 4,620 shares on 11/17/2025 and 10,000 shares on 01/02/2026. The cover block shows 168,903,616 shares outstanding as of 02/17/2026.
Astera Labs filed a Form 144 disclosing a sale of 11,430 shares of common stock by Michael Truett Tate on 11/17/2025. The filing also records a vesting of restricted stock units on 02/15/2026 and identifies Morgan Stanley Smith Barney LLC as the broker.
Astera Labs insider filing to sell shares. The Form 144 discloses an intended sale of 94,971 shares of common stock tied to the vesting of restricted stock units on 02/15/2026. The filing lists a prior sale of 90,459 shares on 11/17/2025.
Astera Labs disclosed a proposed sale of 94,971 shares of common stock tied to the vesting of restricted stock units on 02/15/2026. The filing also shows a prior sale of 90,459 shares on 11/17/2025 reported by Jitendra Mohan. The notice lists the transaction as an issuer-related vesting event.
Astera Labs, Inc. reported an equity award for its Chief Financial Officer, Tate Michael Truett. On February 6, 2026, he received 11,787 restricted stock units of Common Stock at a price of $0 per share, increasing his directly held Common Stock to 204,084 shares.
The RSUs vest 25% on February 15, 2027, with the remaining units vesting in 12 equal quarterly installments, conditioned on his continued service. Separately, 450,281 Common Stock shares are held indirectly by the Tate 1997 Living Trust, where he is a trustee and disclaims beneficial ownership except for any pecuniary interest.
Astera Labs, Inc. insider filing shows new equity compensation for a senior executive. President and COO, and director, Gajendra Sanjay received 26,522 restricted stock units (RSUs) of common stock on February 6, 2026 at a stated price of $0.
The RSUs vest 25% on February 15, 2027, with the remaining units vesting in 12 equal quarterly installments, contingent on his continued service. Following this award, he directly beneficially owns 1,626,272 common shares. Additional common shares are held through three separate estate-planning trusts, where he disclaims beneficial ownership except for any pecuniary interest.
Astera Labs, Inc. reported an equity grant to its Chief Executive Officer and director, Mohan Jitendra. On February 6, 2026, he received 26,522 shares of common stock as restricted stock units at $0 per share under the 2024 Stock Option and Incentive Plan.
The RSUs vest as to 25% on February 15, 2027, with the remaining units vesting in 12 equal quarterly installments, contingent on continued service. Following this grant, he directly holds 1,547,710 shares of common stock. Additional common shares are held indirectly through a living trust and several estate-planning trusts that are associated with him, for which he disclaims beneficial ownership except for any pecuniary interest.